Ependymoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Video
• Funding
• Clinical Trials
• Forums

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
HOUSTON, April 14, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ( " Moleculin " or the " Company " ), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 14, 2021 Category: Pharmaceuticals Source Type: clinical trials

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Conditions:   Recurrent Medulloblastoma;   Recurrent Ependymoma Interventions:   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Omburtamab I-131 Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI);   Memorial Sloan Kettering Cancer Center;   Y-mAbs Therapeutics, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2021 Category: Research Source Type: clinical trials